Cite
HARVARD Citation
Rausch, M. et al. (n.d.). 727 Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors. Journal for immunotherapy of cancer. p. A435. [Online].